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Several small molecule antagonists for Smoothened
(Smo) have been developed, and achieved promising
preclinical efficacy in cancers that are dependent
on Hedgehog (Hh) signaling. However, in a recent
clinical study, a drug-resistant D473H SMO mutant
was identified that is thought to be responsible for
cancer relapse in a patient with medulloblastoma.
Here, we report two Smo antagonists that bind to
distinct sites, as compared to known antagonists
and agonists, and inhibit both wild-type and mutant
Smo. These findings provide an insight of the
ligand-binding sites of Smo and a basis for the devel-
opment of potential therapeutics for tumors with
drug-resistant Smo mutations.
INTRODUCTION
Hedgehog (Hh) signaling is a key signal transduction pathway
regulating embryonic development and tissue regeneration
(Hooper and Scott, 2005; Ingham and McMahon, 2001). In
mammalian cells, binding of Hh ligands (Shh, Ihh, and Dhh)
to the receptor Patched1 (Ptch1) relieves the inhibition of a
GPCR-like protein Smoothened (Smo). Pathway activation ulti-
mately leads to the activation of the Gli family of transcription
factors (Gli1 and Gli2) and induces the expression of down-
stream target genes (Ingham and McMahon, 2001).
It has been shown that aberrant regulation of Hh signaling is
involved in developmental defects and cancers, such as cyclo-
pia, Gorlin’s syndrome, basal cell carcinoma (BCC), and medul-
loblastoma (Epstein, 2008; Rubin and de Sauvage, 2006; Scales
anddeSauvage, 2009;Yauchet al., 2008). Therefore, smallmole-
cule agonists and antagonists of Hh signaling could be useful
therapeutics for the treatment of degenerative diseases and
cancers. Most of the known small molecule regulators of the Hh
pathway bind to Smo, including agonists (purmorphamine,
Hh-Ag 1.2 (SAG) and its derivative Hh-Ag 1.5) and antagonists
(cyclopamine, SANT1, CUR61414, GDC-0449, NVP-LDE225,432 Chemistry & Biology 18, 432–437, April 22, 2011 ª2011 ElsevierIPI-926, etc.) (Chen et al., 2002b; Frank-Kamenetsky et al.,
2002; King, 2002;Mahindroo et al., 2009; Pan et al., 2010; Taipale
et al., 2000; Williams et al., 2003; Wu et al., 2004). Notably, GDC-
0449 showed promising efficacy in phase I/II clinical trials in the
treatment of patients with BCC and medulloblastoma (Rudin
et al., 2009; Von Hoff et al., 2009). However, in the phase I clinical
study of GDC-0449, a drug-resistant mutation in SMO was
identified from the relapsed tumor samples. TheD473Hmutation,
or D477G mutation discovered from a mouse tumor resistant to
GDC-0449, has no effect on Hh signal transduction but disrupts
the binding of antagonist GDC-0449 (Rudin et al., 2009; Yauch
et al., 2009). This finding highlights the need for newHh inhibitors
with alternative mechanisms.
Several known Smo antagonists, including GDC-0449 and
KAAD-cyclopamine, strongly compete with 3H-labeled Hh-Ag
1.2 (SAG) or its derivative, Hh-Ag 1.5, in membrane-binding
assays (Frank-Kamenetsky et al., 2002; Rominger et al., 2009).
In a cell-based Gli-responsive element-Luciferase (Gli-Luc)
reporter assay, these antagonists also showed a significant
decrease in potency when higher doses of agonists (SAG or
Hh-Ag 1.5) were used to induce pathway activation (Table 1)
(Miller-Moslin et al., 2009; Pan et al., 2010). These results
suggest that GDC-0449 and KAAD-cyclopamine strongly
compete with SAG and bind to an overlapping binding site, or
allosterically displace SAG. It is likely that antagonists with the
same binding mode as GDC-0449 might lose pathway inhibition
efficacy in cells harboring the SMO:D473H mutant (or D477G
mutant for mouse Smo) (see Table S1A available online), raising
the concern that relapse might develop quickly as a result of the
acquisition of the drug-resistant D473H mutation in tumors
treated with this type of antagonist. Therefore, identification of
small molecule antagonists that can inhibit the D473H (or mouse
D477G) mutant Smo would be important for cancer drug
discovery (Dijkgraaf et al., 2011).
RESULTS AND DISCUSSION
Identification of Hh Antagonists
By high throughput screening, we identified two Hh signaling
inhibitors from commercial compound libraries (approximately
50,000 compounds from Maybridge and ChemDiv), namedLtd All rights reserved
Table 1. IC50 (nM) Values of Hh Antagonists in TM3-Gli-Luc
Reporter Assay and Control Assays
Assay ALLO-1 ALLO-2
KAAD-
Cyclopamine
TM3-Gli-Luc: 1 nM Hh Ag1.5 33 5.6 9.7
TM3-Gli-Luc: 25 nM Hh Ag1.5 55 5.9 160
TM3-Gli-Luc: recombinant ShhN 320 39 60
TM3-Gli-Luc-Smo-WT 410 41 81
TM3-Gli-Luc-Smo:D477G 1000 83 1700
TM3 cell viability >10 mM >10 mM 3.1 mM
293 Wnt-responsive TopFlash >10 mM >10 mM ND
TM3 SV40-Luc >10 mM 7.1 mM ND
293 NFlB responsive-Luc >10 mM >10 mM ND
See also Table S1. ND, not determined.
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induced luciferaseexpression inTM3-Gli-Luccells, a stableclone
of mouse TM3 cells expressing Gli-Luc reporter (see Supple-
mental Experimental Procedures for detailed information; Fig-
ure 1A) (Miller-Moslin et al., 2009; Pan et al., 2010). The potency
of the compounds did not change when either low dose (1 nM)
or high dose (25 nM) of Hh-Ag 1.5 was used, in contrast to other
known Smo antagonists that are strong SAG or Hh-Ag 1.5
competitors (Chen et al., 2002b; Miller-Moslin et al., 2009).
ALLO-1 inhibited Gli-Luc activity with an IC50 around 50 nM,
and ALLO-2 had an IC50 around 6 nM (Figures 1B and 1C and
Table 1). Both compounds also inhibited recombinant N-terminal
Shh ligand (ShhN)-induced pathway activationwith IC50 values of
320 and 39 nM, respectively (Figure 1D and Table 1). The inhibi-
tion of the Gli-Luc reporter was not a result of cytotoxicity or
nonspecific transcriptional or translational inhibition because
these compounds showed >100-fold window in a cell viability
assay and did not inhibit other luciferase reporters under the
control of constitutively active or Hh nonresponsive promoters,
such as SV-40 promoter, Wnt-responsive SuperTopFlash, and
NF-kB responsive element (Figures 1B and 1Cand Table 1). Their
inhibitory activities in human HEPM and mouse NIH 3T3 cells
were further confirmed by the inhibition of human GLI1 and
PTCH1 or mouse Gli1 mRNA expression induced by ShhN, as
determined by qRT-PCR (Figures 1E and 1F; Figure S1). ALLO-1
and ALLO-2 showed IC50 values of 805 and 40 nM in mouse
Gli1 qRT-PCR assays, respectively. Both compounds dose
dependently inhibited the ShhN-induced proliferation of mouse
cerebella granule neuron progenitors (CGNPs), with IC50 values
of 410 and 22 nM, respectively, similar to that of the pathway inhi-
bition in reporter assays (Figure 1G; FigureS1). Furthermore, both
compounds inhibited the proliferation of Ptch1+/p53/ mouse
medulloblastoma cells in a dose-dependent manner, with IC50
values of 0.47 and 0.12 mM, respectively (Figure 1H). Although
ALLO-2 shares structural similarities with protein kinase inhibi-
tors, it showed no significant inhibition at 5 mM with respect of
a panel of 99 kinases (Invitrogen kinase profiling, Table S1B).
ALLO-1 and ALLO-2 Are Smo Antagonists with Different
Binding Modes
Neither ALLO-1 nor ALLO-2 inhibits Hh pathway activation
induced by siRNA knockdown of Suppressor of Fused (SuFu),Chemistry & Biology 18,suggesting that these compounds act at a level upstream of
SuFu in the signal transduction cascade (Figure S2). To deter-
mine whether these compounds directly target Smo, we then
carried out membrane-binding assays using 3H-labeled agonist
(Hh-Ag 1.5) or antagonist (cyclopamine). In contrast to other
known Smo antagonists (Chen et al., 2002b; Miller-Moslin
et al., 2009; Pan et al., 2010; Rominger et al., 2009), ALLO-1
and ALLO-2 did not compete with [3H]Hh-Ag 1.5 (Figure 2A),
consistent with their noncompetitive characteristics in reporter
assays. However, ALLO-2 competed with [3H]cyclopamine,
with an IC50 of 2.8 nM, whereas ALLO-1 did not (Figure 2B).
We also tested whether these compounds compete with
BODIPY-cyclopamine, a fluorescent derivative of cyclopamine,
using an imaging-based fluorescent-binding assay (Chen et al.,
2002a; Pan et al., 2010). Both ALLO-1 and ALLO-2 effectively
competed with BODIPY-cyclopamine in CHO-K1 cells overex-
pressing wild-type Smo, with IC50 values of 140 and 2.8 nM,
respectively (Figure 2C; Figure S2). Because the fluorescent-
binding assay was done with fixed cells, the competition of
binding does not implicate a conformational change or the
recruitment of effector proteins (Chen et al., 2002a; Taipale
et al., 2000). It was reported that BODIPY-cyclopamine and
KAAD-cyclopamine have significantly improved potency com-
pared to cyclopamine in Hh signaling inhibition (Chen et al.,
2002a); therefore, an additional binding site that accommodates
the BODIPY or KAADmoiety may exist (or is induced) adjacent to
the cyclopamine-binding site. Given the fact that ALLO-1
competes with BODIPY-cyclopamine, but not [3H]cyclopamine,
it is possible that the binding site of ALLO-1 might be located in
the site accommodating the BODIPY moiety. ALLO-1, BODIPY,
and KAAD all contain a hydrophobic phenyl ring; thus, the
binding site accommodating these motifs may be hydrophobic.
It is known that cyclopamine competes with SAG or Hh-Ag 1.5,
suggesting that the binding sites of cyclopamine and Hh-Ag 1.5
overlap, at least partially (Chen et al., 2002a; Rominger et al.,
2009). Because ALLO-2 competes with [3H]cyclopamine, but
not [3H]Hh-Ag 1.5, we speculate that the ALLO-2 binding site
does not overlap with Hh-Ag 1.5 but may partially overlap with
cyclopamine. Taken together, these experiments suggest that
both ALLO-1 and ALLO-2 bind to Smo but might have different
binding modes from previously known Smo antagonists. It
was previously hypothesized that SAG or Hh-Ag 1.5-binding
sites may be different from cyclopamine or other antagonists’
binding sites (Chen et al., 2002a; Frank-Kamenetsky et al.,
2002; Rominger et al., 2009). Our data suggested that antago-
nists such as ALLO-1 and ALLO-2 could occupy sites distinct
from the SAG or Hh-Ag 1.5-binding sites and are noncompetitive
with the SAG binding. Therefore, multiple binding sites for
different compounds might exist and partially overlap with
each other in Smo.
ALLO-1 and ALLO-2 Inhibit Drug-Resistant Smo Mutant
Because ALLO-1 and ALLO-2 bind to Smo differently than GDC-
0449 and other Smo antagonists, we hypothesized that they
might be active against the drug-resistant Smomutant.We over-
expressed both wild-type mouse Smo and the D477G mutant
Smo with GFP tagged at the C termini in the TM3-Gli-Luc
reporter cell line, and determined pathway inhibition with these
compounds. The wild-type and D477G Smo variants were432–437, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 433
Figure 1. ALLO-1 and ALLO-2 Inhibit Hh Signaling
(A) The structures of ALLO-1 and ALLO-2.
(B andC) The inhibition of Gli-Luc reporter activity by ALLO-1 (B) and ALLO-2 (C) in TM3-Gli-Luc cells stimulated with 1 nM (red), 5 nM (blue), or 25 nM (green) Smo
agonist Hh-Ag 1.5; and the inhibition to luciferase activity in TM3 cells expressing SV40-Luc (black) (n = 3). Values are mean ± standard deviation (SD). Represent
at least three independent experiments.
(D) The inhibition of Gli-Luc reporter activity by ALLO-1 (red) and ALLO-2 (black) in TM3-Gli-Luc cells stimulated with recombinant ShhN (200 ng/ml) (n = 3). Values
are mean ± SD. Represent at least three independent experiments.
(E) Both ALLO-1 (20, 2, and 0.2 mM) and ALLO-2 (5, 0.5, and 0.05 mM) inhibit recombinant ShhN (200 ng/ml) induced GLI1 expression in human HEPM cells
(C, DMSO control; n = 2; mean ± SD). Represent two independent experiments.
(F) Both ALLO-1 and ALLO-2 inhibit recombinant ShhN-induced Gli1 expression in NIH 3T3 cells dose dependently. mRNA expression was normalized against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control (n = 3; mean ± SD).
(G) Both ALLO-1 (red) and ALLO-2 (black) inhibit ShhN-induced mouse CGNPs proliferation in a dose-dependent manner (n = 2; mean ± SD).
(H) Both ALLO-1 (red) and ALLO-2 (black) inhibit Ptch1+/p53/ mouse medulloblastoma cell proliferation in a dose-dependent manner (n = 3; mean ± SD).
All assays were normalized using DMSO treatments (control).
See also Figure S1.
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imaging (Figure S3). Consistent with previous reports, GDC-
0449 has an IC50 of 7.8 mM in TM3 cells overexpressing D477G
mutant Smo, whereas it inhibits TM3-Gli-Luc cells overexpress-
ing wild-type Smo with an IC50 of 42 nM (Figure 3A; Table S1). In
contrast to GDC-0449, both ALLO-1 and ALLO-2 inhibit wild-
type and the D477G mutant with only 2-fold shift in IC50, sug-
gesting that the D477G mutation does not significantly interfere
with the binding of ALLO-1 and ALLO-2 to Smo (Figures 3B and
3C and Table 1). Furthermore, ALLO-1 and ALLO-2 inhibit both
wild-type and D473H mutant human SMOwith similar potencies
(Figure S3). Interestingly, SANT1 also inhibits Hh signaling in cells
overexpressing the drug-resistant Smo mutant, with less severe
(10-fold) loss of potency when compared to GDC-0449 and
cyclopamine (>20-fold IC50 shift) (Table S1). It was reported
that SANT1 allosterically inhibits SAG-induced pathway activa-434 Chemistry & Biology 18, 432–437, April 22, 2011 ª2011 Elseviertion, consistent with our hypothesis that compounds with
different binding modes might inhibit GDC-0449-resistant
D477G mutant more effectively (Chen et al., 2002b; Rominger
et al., 2009). Furthermore, we tested whether ALLO-1 and
ALLO-2 could inhibit the proliferation of Ptch1+/p53/ mouse
medulloblastoma cells harboring the drug-resistant D477G
mutant Smo. We infected Ptch1+/p53/ mouse medulloblas-
toma cells with lentivirus carrying wild-type Smo or D477G
mutant Smo expression vectors, and treated cells with Smo
antagonists. Consistent with the reporter assay results, GDC-
0449 inhibited the proliferation of medulloblastoma cells
overexpressing wild-type Smo but was less potent in cells over-
expressing D477G mutant Smo, with IC50 values of 23 nM for
wild-type Smo and 3.2 mM for D477G mutant Smo expression
cells. In contrast, ALLO-1 and ALLO-2 showed similar antiprolif-
eration activities on both cell lines (Figures 3D–3F). ALLO-1 hasLtd All rights reserved
Figure 2. ALLO-1 and ALLO-2 Bind to Smo
(A) ALLO-1 (red triangles) and ALLO-2 (black dots) do not compete with [3H]
Hh-Ag 1.5, whereas a control compound (NVP-LDE225, black circles) (Pan
et al., 2010) showed a dose-dependent competition (for ALLO-1 and ALLO-2,
n = 2; mean ± SD).
(B) ALLO-2 (black), but not ALLO-1 (red), competes the binding of [3H]cy-
clopamine to Smo (n = 2; mean ± SD).
(C) ALLO-1 (red) and ALLO-2 (black) compete the binding of BODIPY-cy-
clopamine to Smo (n = 2; mean ± SD). All assays were normalized using DMSO
treatments (control).
See also Figure S2.
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Chemistry & Biology 18,IC50 values of 489 nM for wild-type Smo and 1.2 mM for D477G
Smo expression cells. ALLO-2 has IC50 values of 132 nM for
wild-type Smo and 440 nM for D477G Smo expression cells.
Finally, we tested whether ALLO-1 and ALLO-2 can inhibit the
Hh signaling activated by a previously known oncogenic
Smo:W539L (SmoM2) mutant, to which cyclopamine signifi-
cantly loses its antagonist activity (Chen et al., 2002a, 2002b).
ALLO-1 inhibited SmoM2-induced Gli1 expression in NIH 3T3
cells, whereas ALLO-2 did not (Figure S3). Interestingly, as we
showed in membrane-binding assays, ALLO-1 does not
compete with [H3]cyclopamine to bind to Smo. These results
suggest that W539L mutation might disrupt cyclopamine
binding, but antagonists that are noncompetitive with cyclop-
amine can bind to and inhibit SmoM2 mutant.
SIGNIFICANCE
Although, toourknowledge, there isnohigh-resolutionstruc-
tural information or detailedmutagenesis study of Smoavail-
able to date, our report here suggest that there are multiple
ligand-binding sites in Smo that accommodate the binding
of diverse compounds, as ALLO-1 and ALLO-2 do not
compete with SAG and Hh-Ag1.5 and behave differently for
competing cyclopamine. Oncogenic mutations such as
W539L and drug-resistant mutations such as D473H might
disrupt one small molecule-binding site, but ligands that
bind to other sites are not affected, although additional Smo
mutationscouldarise for these ligands in tumors. In summary
our work describes two Smo antagonists with distinct
binding modes and gives a new insight for the Smo ligand-
binding sites. Derivatives of these compounds with appro-
priate pharmacological properties could be useful tools to
explore therapies for tumors with SMOmutations in vivo.
EXPERIMENTAL PROCEDURES
Constructs
Drug-resistant D477G Smo expression vectors were generated by using Quik-
Change Site-DirectedMutagenesis Kit (Stratagene, La Jolla, CA,USA) from the
wild-type Smo construct using the following primers: 50-CTT CAG CTG CCA
CTT CTA TGG CTT CTT CAA CCA GGC TG, and 50-CAG CCT GGT TGA AGA
AGC CAT AGA AGT GGC AGC TGA AG. Smo-GFP expression vector was
constructed by subcloning eGFP ORF from pEGFP-N1 construct (Clontech,
Mountain View, CA, USA) into the Smo expression vectors, using primers
forward (50-GCA TAC GTC GCT AGC AGG ATC GGT GAG CAA GGG CGA
GGA G) and reverse (50-GCA TAC AGC GTC GAC TTA CTT GTA CAG CTC
GTCC) with NheI and SalI (New England Biolabs, Ipswich, MA, USA) digestion.
The lentiviral Smo (wild-type and D477G mutant) expression vectors were
generated by cloning of a 3 kb fragment containing wild-type or mutant Smo
ORF digested by NdeI and XbaI restriction enzymes (New England Biolabs)
to a pLVX-IRES-Neo lentiviral vector (Clontech). SmoM2 mutant construct is
kindly provided by James Chen, Stanford University. Human SMO D473H
mutant was generated as reported previously (Buonamici et al., 2010).
Lentiviral Particle Production and Cell Infection
Lentiviral particles carrying Smo-GFP and Smo:D477G-GFP genes were
generated in 293T cells (ATCC, Manassas, VA, USA) by cotransfecting pack-
aging vectors (VSV-G, REV, and RRE; Clontech) and the Smo vectors using
Fugene 6 transfection reagent (Roche Applied Science) following manufac-
turer’s recommendation. Viral supernatants were collected 48 hr post-trans-
fection and purified using Amicon filters (Millipore, Billerica, MA, USA). TM3-
Gli-Luc cells were infected with serial dilutions of lentivirus supernatant, and432–437, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 435
Figure 3. ALLO-1 and ALLO-2 Inhibit Drug-Resistant Smo:D477G Mutant
(A–C) The inhibition of Gli-Luc reporter activity by GDC-0449 (A), ALLO-1 (B), and ALLO-2 (C) in TM3-Gli-Luc cells overexpressing wild-type Smo-GFP (filled
symbols) or Smo:D477G-GFP (open symbols). Represent three independent experiments.
(D–F) The inhibition to cell proliferation by GDC-0449 (D), ALLO-1 (E), and ALLO-2 (F) to medulloblastoma cells overexpressing wild-type Smo-GFP (filled
symbols) or Smo:D477G-GFP (open symbols). All assays were normalized to the DMSO treatments (control).
See also Figure S3.
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experiments. The cells expressing desired Smo-GFP were collected using BD
FACSVantage SE cell sorter and analyzed using BD FACSDiva software (BD
Biosciences, San Jose, CA, USA). Expression of GFP was confirmed using
a Nikon Eclipse TE300 fluorescent microscope.
Cell-Based Reporter Assay
TM3 cells are from ATCC, and the reporter cell line (TM3-Gli-Luc) was gener-
ated as reported before (Miller-Moslin et al., 2009; Pan et al., 2010) and is
briefly described in the Supplemental Experimental Procedures. TM3-Gli-
Luc cells are cultured in F12 Ham’s/DMEM (1:1) medium containing 5% horse
serum, 2.5% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA). Cells
were harvested by trypsin treatment, and were plated in 384-well assay plates
in 40 ml of F12 Ham’s/DMEM (1:1) containing 2% FBS with a density of 5000
cells/well. Hh antagonists were dissolved in DMSO with serial dilutions and
were then added to the assay plate using 100 nl Pintool head (GNF, San Diego,
CA, USA). Hh-Ag 1.5 (synthesized in house), or recombinant ShhN (200 ng/ml;
R&D Systems, Minneapolis) or mouse Shh conditioned medium (10 ml,
prepared by using 293 EcR Shh cell line obtained from ATCC under a license
agreement between Novartis and Johns Hopkins University, following the
protocols suggested by ATCC) in 10 ml of assay media was added 30min later.
The assay plates were incubated at 37C for 48 hr and were assayed using
Bright-Glo reagent (Promega, Madison, WI, USA) according to manufacturer’s
protocol. Luminance signals were read using Chemiluminescence Imaging
Plate Reader (CLIPR) System (Molecular Devices, Sunnyvale, CA, USA). Lumi-
nance reading for TM3-Gli-Luc assay was normalized based on DMSO control
(100% of pathway activity) and a known Smo antagonist (GDC-0449 at 10 mM,
0% of pathway activity). IC50 values, defined as the inflection point of the
logistic curve, were determined by nonlinear regression using the Prism 4 soft-
ware (GraphPad, La Jolla, CA, USA). The reporter assay of TM3-Gli-Luc cells
infected with wild-type, D477H mutant Smo mutant was carried out with the
same protocol.
TaqMan Gene Expression Assay
Endogenous mouse Gli1 and Ptch1 or human GLI1 and PTCH1 gene expres-
sionwas performed usingmouse NIH 3T3 or human embryonic palatal mesen-
chymal (HEPM) cells (ATCC). NIH 3T3 and HEPM cells were cultured in 6-well
plate and treated for 48 hr with recombinant ShhN (200 ng/ml) and Smo antag-
onists or DMSO control in EMEM medium containing 0.5% FBS. Total RNAs436 Chemistry & Biology 18, 432–437, April 22, 2011 ª2011 Elsevierwere harvested using TRIzol reagent (Invitrogen), extracted using chloroform,
and purified using RNeasy Mini Spin Column (QIAGEN, Valencia, CA, USA)
according to manufacturer’s protocol. RNAs were reverse transcribed by
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA). TaqMan Gene Expression Assays (Applied Biosystems;
Mm00494645_m1 for mouse Gli1, Mm00436026_m1 for mouse Ptch1,
Hs00171790_m1 for human GLI1, and Hs00181117_m1 for human PTCH1)
were used for quantitative expression analyses, and GAPDH TaqMan assays
with VIC/MGBProbe (Applied Biosystems; 4352339E for mouse; 4326317E for
human) were used as endogenous controls. Real-time PCR was performed
using the TaqMan Gene Expression Master Mix and ABI Prism 7900HT fast
real-time PCR system (Applied Biosystems).
Fluorescence-Binding Assays
Fluorescence competition-binding assays using BODIPY-cyclopamine were
conducted as described (Pan et al., 2010). Briefly, binding assays were con-
ducted in 384-well plates using fixed CHO-K1 cells stably expressing mouse
Smo. Cells were fixed with 4% paraformaldehyde for 15 min at room temper-
ature, washed, covered in PBS containing 0.5% FBS, and incubated with
20 nM BODIPY-cyclopamine (Toronto Research Chemicals, Ontario, Canada)
and Smo antagonists for 4 hr at 37C. The treated cells then were washed with
PBS three times, nuclear stained with Hoechst 33258, and analyzed by Image-
Xpress Ultra imaging system (Molecular Devices, Carlsbad, CA, USA).
Membrane-Binding Assays
Membrane-binding assays were conducted as described (Miller-Moslin et al.,
2009) in 96-well plates. Briefly, Smomembranes were prepared from CHO-K1
cells that were stably transfected with cDNA encoding mouse Smo. Binding
buffer (50 mM Tris buffer [pH 7.5], 5 mM MgCl2, 1 mM EDTA, 0.1% bovine
serum albumin), 0.17 mg/ml of Smo membranes, 7 nM [3H]cyclopamine, or
0.3 nM [3H]Hh-Ag 1.5 with various concentrations of Smo antagonists in a total
volume of 150 ml were incubated at 37C for 3 hr, and the assays were termi-
nated by filtration through 96-well fiberglass FB filtration plates precoated with
0.1% BSA (Millipore, Bedford, MA, USA), and then the filtration plates were
washed three times with washing buffer (50 mM Tris buffer [pH 7.5], 5 mM
MgCl2, 1 mM EDTA, 0.1% bovine serum albumin, and 0.05% (2-Hydroxy-
propyl) cyclodextrin). The plate was added with scintillation cocktail and
read on a TopCount Microplate Scintillation Counter (Perkin Elmer, Waltham,
MA, USA).Ltd All rights reserved
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CGNPs were isolated from 4-day-old (P4) C57BL/6 mice as described (Hatten
et al., 1998). CGNPs were cultured on poly-D-lysine-coated 384-well plates in
Neurobasal medium containing 2%B-27 supplement, 1 mM sodium pyruvate,
2 mM L-glutamine, and 1% Penicillin/Streptomycin supplement (Invitrogen) at
2 3 105 cells per well. Recombinant ShhN (200 ng/ml) and antagonists were
added. Cell proliferation assay was performed using Click-iT EdU Cell Prolifer-
ation Assay kit (Invitrogen) following manufacturer’s protocol. Briefly, cells
were pulsed with 5 mM EdU (5-ethynyl-20-deoxyuridine; Invitrogen) for 12 hr,
and then were fixed with 4% paraformaldehyde, permeabilized with PBS con-
taining 0.5% Triton X-100, washed, and incubated with detection cocktail con-
taining 500 nM Alexa Fluor 488 azide, 1 mM CuSO4, and 5 mM ascorbic acid
for 30 min at room temperature. The treated cells were then washed with PBS,
nuclear stained with Hoechst 33258, and analyzed by ImageXpress Ultra
imaging system (Molecular Devices, Mountain View, CA, USA).
Medulloblastoma Proliferation Assay
Tumors derived from Ptch+/p53/ transgenic mice were serially passaged
as fragments in nude mice. Ptch+/p53/ medulloblastoma cells were iso-
lated frommouse allograft as described (Buonamici et al., 2010). Medulloblas-
toma cells were cultured on a nonadherent 10 cm Petri dish in Neurobasal
Medium containing 2% B-27, 1% N2 supplement, and 1% Penicillin/Strepto-
mycin (Invitrogen) with 13 107 cells per dish. After 3 days of culture, cells were
then infected with lentiviral supernatants carrying either wild-type or D477G
mouse Smo-GFP vectors. Expression levels of Smo were confirmed by RT-
PCR. Cell proliferation was assayed as described above using Click-iT EdU
Cell Proliferation Assay kit (Invitrogen).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
doi:10.1016/j.chembiol.2011.01.018.
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